×
About 489,273 results

Fischer & Wieser Specialty Foods Issues Voluntary Recall of H-E-B Creamy Tomato Basil Soup
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/442737

Committed to the quality of its products, Fischer & Wieser Specialty Foods is recalling 31.4-ounce jars of H-E-B Creamy Tomato Basil Soup due to the possible presence of glass in the product.

FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma Following CR
https://www.onclive.com/view/fda-approves-adjuvant-pembrolizumab-for-stage-iib-or-iic-melanoma-following-cr

Dec 4th, 2021 - The FDA has approved pembrolizumab (Keytruda) for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection (CR). The regulatory agency also expanded the indication for the immunotherapy for adjuvant use in patients with stage III melanoma following CR to include pediatric patients aged 12 yers and older. The indication for the agent's ...

Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests ...
https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2
MedWatch; FDA

Dec 3rd, 2021 - UPDATE: For additional information on the impact of SARS-CoV-2 viral mutations, including the latest list of authorized tests whose performance could be impacted by SARS-CoV-2 viral mutations, see SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. January 8, 2021 The SARS-CoV-2 virus can mutate over time, resulting in genetic variation in the population of circulating viral strains. The U.S....

Fauci: 'Every Reason To Believe' Boosters Protect Against Omicron
https://www.medpagetoday.com/infectiousdisease/covid19/96008

Dec 3rd, 2021 - Vaccination with a booster dose of COVID vaccine is expected to offer "some degree of cross protection" against the Omicron variant, said NIAID Director Anthony Fauci, MD, during a White House COVID-19 Response Team briefing on Friday. While there are still a lot of unknowns when it comes to the new variant -- including how transmissible it is, the severity of disease it causes, and its ability...

Brexucabtagene Autoleucel Expands Treatment Possibilities in ALL
https://www.onclive.com/view/brexucabtagene-autoleucel-expands-treatment-possibilities-in-all

Dec 3rd, 2021 - Based on data from the phase 1/2 ZUMA-3 trial (NCT02614066), the FDA has approved the CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy brexucabtagene autoleucel (Tecartus) for the treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). In 54 evaluable patients, 51.9% (95% CI, 37.8%-65.7%) achieved complete remission (CR) within 3...

High Altitudes Mess With CPR Skills in Trained EMS Personnel
https://www.medpagetoday.com/emergencymedicine/emergencymedicine/96002

Dec 3rd, 2021 - High altitude hurt the quality of chest compressions from trained rescuers without them realizing it, experiments showed. At simulated altitudes of 200, 3,000, or 5,000 meters in a hypobaric chamber, helicopter EMS personnel started out with optimal chest compressions on manikins, but gradually lost both the depth in their compressions and the proper pacing of effective compressions over time, ...

Liso-cel Significantly Prolongs EFS Over SOC in Second-Line Relapsed/Refractory LBCL
https://www.onclive.com/view/liso-cel-significantly-prolongs-efs-over-soc-in-second-line-relapsed-refractory-lbcl

Dec 3rd, 2021 - Lisocabtagene maraleucel (Breyzani; liso-cel) significantly prolonged event-free survival (EFS) and progression-free survival and improved complete responses (CRs) compared with standard of care (SOC) when used in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL), according to data from a prespecified interim analysis of the phase 3 TRANSFORM trial (...

Dementia Tied to Resting Heart Rate
https://www.medpagetoday.com/neurology/dementia/95999

Dec 3rd, 2021 - Higher resting heart rate (RHR) was linked to greater dementia risk and faster cognitive decline independent of cardiovascular disease in a study of more than 2,000 older adults in Sweden. People with RHR of 80 bpm or higher had a 55% increased risk of developing dementia compared with people whose RHR was 60-69 bpm (adjusted HR 1.55, 95% CI 1.06-2.27), reported Yume Imahori, MD, PhD, of the Ka...

Hospitals refused to give patients ivermectin. Lockdowns and political pressure followed.
https://www.mdedge.com/infectiousdisease/article/249430/covid-19-updates/hospitals-refused-give-patients-ivermectin
Matt Volz, Kaiser Health News

Dec 3rd, 2021 - One Montana hospital went into lockdown and called police after a woman threatened violence because her relative was denied her request to be treated with ivermectin. Officials of another Montana hospital accused public officials of threatening and harassing their health care workers for refusing to treat a politically connected COVID-19 patient with that antiparasitic drug or hydroxychloroquin.

Arrow International Inc Recalls Arrow-Trerotola Over-The-Wire PTD Kit Percutaneous Thro...
https://www.fda.gov/medical-devices/medical-device-recalls/arrow-international-inc-recalls-arrow-trerotola-over-wire-ptd-kit-percutaneous-thrombolytic-device
MedWatch; FDA

Dec 3rd, 2021 - The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. The Arrow-Trerotola Over-The-Wire (PTD) Kit Percutaneous Thrombolytic Device: 7FR includes a rotatable catheter with an outer sheath and an inner cable with a self-expanding basket. The Arrow-Trerotola Percutaneous Thrombolyic Device (PTD) Catheter is used ...

Therapeutic Advances in Prophylaxis Against CIN
https://www.onclive.com/view/therapeutic-advances-in-prophylaxis-against-cin

Dec 3rd, 2021 - Hope S. Rugo, MD, FASCO: We’ve talked about some really interesting areas today. I appreciate everybody’s thoughts and input, and I think I’ve learned a lot about managing CIN [chemotherapy-induced neutropenia], this new interesting agent, a SIMBA [selective immunomodulating microtubule binding agent], as well as some of the other studies that are going on and the approval of trilaciclib. As we...

Cannabis Use Climbing in Pregnancy Among People With HIV
https://www.medpagetoday.com/obgyn/pregnancy/95996

Dec 3rd, 2021 - Among pregnant people living with HIV, marijuana use climbed over the last decade both in pregnancy and during the postpartum period, according to results from a cohort study. Prevalence of marijuana use during pregnancy among people living with HIV increased from 7.1% in 2007 to 11.7% in 2019, reported Lynn Yee, MD, MPH, of Northwestern University Feinberg School of Medicine, and colleagues. D...

Omicron Creep Begins; Autism Cases Jump; States Ready Abortion Restrictions, Bans
https://www.medpagetoday.com/infectiousdisease/covid19/95989

Dec 3rd, 2021 - Note that some links may require registration or subscription. New York health officials have identified five cases of the Omicron coronavirus variant in Long Island, Queens, and Brooklyn. (Gothamist) Officials in Minnesota and Colorado announced the first cases of Omicron infection in their respective states. (Reuters, Denver Post) A confirmed Omicron case in Hawaii raised the number of affect...

Frontline Pembrolizumab Plus Chemotherapy Approved in Japan for Esophageal Carcinoma
https://www.onclive.com/view/frontline-pembrolizumab-plus-chemotherapy-approved-in-japan-for-esophageal-carcinoma

Dec 3rd, 2021 - The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has approved the PD-1 inhibitor pembrolizumab (Keytruda) for frontline use in combination with 5-fluorouracil (5-FU) plus cisplatin chemotherapy in patients with radically unresectable, advanced, or recurrent esophageal carcinoma, according to a news release from Merck, the manufacturer of pembrolizumab.1 The approval represents the f...

Dr. Leal on the Evolution of Treatment in EGFR Exon 20 Insertion+ NSCLC
https://www.onclive.com/view/dr-leal-on-the-evolution-of-treatment-in-egfr-exon-20-insertion-nsclc

Dec 2nd, 2021 - Ticiana Leal, MD, associate professor, director, Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC). Historically, patients with advanced NSCLC harboring EGFR exon 20 inser...

Dr. Pothuri on the Challenges of POLE Testing in Endometrial Cancer
https://www.onclive.com/view/dr-pothuri-on-the-challenges-of-pole-testing-in-endometrial-cancer

Dec 2nd, 2021 - Bhavana Pothuri, MD, professor, departments of Obstetrics and Gynecology and Medicine, NYU Grossman School of Medicine, director, Gynecologic Oncology Clinical Trials, NYU Langone Health’s Perlmutter Cancer Center, discusses the challenges of DNA polymerase epsilon (POLE) mutation testing in endometrial cancer. POLE mutation testing requires tissue-based next-generation sequencing, so it ca...

No new prognostic factors for mortality following bacteremia in severe pneumococcal community-acquired pneumonia
https://www.mdedge.com/chestphysician/article/249426/community-acquired-pneumonia/no-new-prognostic-factors-mortality

Dec 2nd, 2021 - Key clinical point: Development of bacteremia in immunocompetent adult patients managed in the ICU for severe pneumococcal community-acquired pneumonia (CAP) had no effect on mortality. Main finding: In-hospital mortality (21.

Dr. Lee on Treatment Considerations in Smoldering Multiple Myeloma
https://www.onclive.com/view/dr-lee-on-treatment-considerations-in-smoldering-multiple-myeloma

Dec 2nd, 2021 - Sarah S. Lee, MD, physician, Seattle Cancer Care Alliance, assistant professor, Division of Medical Oncology, University of Washington School of Medicine, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses treatment considerations in smoldering multiple myeloma. Because a significant amount of research is ongoing for patients with smoldering multi...

Dr. Allison on the Urgency of Drug Development in Oncology
https://www.onclive.com/view/dr-allison-on-the-urgency-of-drug-development-in-oncology

Dec 2nd, 2021 - James P. Allison, PhD, chair, Immunology, executive director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, recipient, 2018 Nobel Prize in Physiology or Medicine, discusses his experience with the urgency of drug development in oncology.  There was a lot of urgency in the early days of developing ipilimumab (Yervoy) when the antibody was made, Allison says. In the ...

Dr. Thaker on the Importance of Surveying Patients on Unmet Needs in Ovarian Cancer
https://www.onclive.com/view/dr-thaker-on-the-importance-of-surveying-patients-on-unmet-needs-in-ovarian-cancer

Dec 2nd, 2021 - Premal Thaker, MD, MS, professor, Obstetrics and Gynecology, director, Gynecological Oncology Clinical Research, Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the importance of surveying patients on unmet needs in ovarian cancer.  The Association of Community Cancer Centers (ACCC) recently initiated a multiphase study in 2019 with ...